In its September issue, Prevention magazine – in its “Need to Know: Medical Breakthroughs” section – has this headline:
The brief story that follows trumpets one study in five mice, and then reveals that human trials are expected to begin in early 2014. Begin, not wrap up. Yet Prevention already calls it a “silver bullet.”
Here are some definitions I found for the term “silver bullet”:
I don’t know what definition Prevention had in mind when it headlined this “breakthrough.” But I do know that 4 months followup in five mice does not translate immediately to a fail-safe, infallible, or simple remedy for a human.
I found something on Stanford’s website which I believe relates to the work Prevention hyped. (I can only guess since the magazine didn’t cite a reference, nor any researchers’ names.) There is no hype in the Stanford article. In fact, it paints a sobering picture of how huge is the leap from mouse to human applicability. Excerpt:
“Unfortunately, the process of preparing for human clinical trials is long. The initial experiments were done in animals and the animal versions of anti-CD47 antibody cannot be used in humans. So researchers first have to create a “humanized” antibody to CD47, then the production of antibody must be scaled up in a sterile facility of the kind that is used to create other pharmaceutical products. Finally, clinical trials must be designed so that the data they generate will produce a valid scientific result, and the trials must be approved by regulatory officials.
All of this takes time.”
So, no human cancer breakthrough yet. No silver bullet yet. Breathe deeply and move on carefully to the next “need to know” piece.
Follow us on Facebook, and on Twitter: